{"id":39409,"title":"protocol_template_for_intervention_review","title_html":"<p>protocol_template_for_intervention_review<\/p>","image":{"source":"https:\/\/www.protocols.io\/img\/default_protocol.png","placeholder":"https:\/\/www.protocols.io\/img\/default_protocol.png"},"doi":"dx.doi.org\/10.17504\/protocols.io.biqrkdv6","doi_status":2,"uri":"protocol-template-for-intervention-review-biqrkdv6","type_id":4,"template_id":3,"published_on":1595025161,"parent_protocols":[],"parent_collections":[],"cited_protocols":[],"version_id":0,"created_on":1595024852,"categories":null,"creator":{"name":"Yuki Kataoka","affiliation":null,"affiliations":[{"affiliation":null,"url":null,"is_default":1}],"username":"yuki-kataoka","link":null,"image":{"source":"\/img\/avatars\/011.png","placeholder":"\/img\/avatars\/011.png"},"badges":[{"id":2,"image":{"source":"\/img\/badges\/bronze.svg","placeholder":"\/img\/badges\/bronze.svg"},"name":"Author"},{"id":5,"image":{"source":"\/img\/badges\/star.svg","placeholder":"\/img\/badges\/star.svg"},"name":"Early adopter"}],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},"journal":null,"journal_name":null,"journal_link":null,"article_citation":null,"public":1,"has_versions":0,"link":null,"total_collections":0,"number_of_steps":0,"authors":[{"name":"Yuki Kataoka","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":"yuki-kataoka","link":null,"image":{"source":"\/img\/avatars\/011.png","placeholder":"\/img\/avatars\/011.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Yasushi Tsujimoto","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Masahiro Banno","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":"m4tle142u105qle1","link":null,"image":{"source":"\/img\/avatars\/003.png","placeholder":"\/img\/avatars\/003.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Shunsuke Taito","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":"m4tle1z1z1z4ule1","link":null,"image":{"source":"\/img\/avatars\/017.png","placeholder":"\/img\/avatars\/017.png"},"badges":[],"verified":1,"is_verified_user":true,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Ryuhei So","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Jun Watanabe","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false},{"name":"Akihiro Shiroshita","affiliation":"Syatematic Review Work Shop-Peer Support Group","affiliations":[],"username":null,"link":null,"image":{"source":null,"placeholder":null},"badges":[],"verified":0,"is_verified_user":false,"research_interests":null,"blocked_by_you":false,"blocked_you":false,"hide_following":false}],"versions":[],"groups":[],"is_owner":1,"has_subprotocols":0,"is_subprotocol":1,"is_bookmarked":0,"can_claim_authorship":0,"can_accept_authorship":0,"can_be_copied":1,"can_remove_fork":1,"fork_id":null,"url":"https:\/\/www.protocols.io\/view\/protocol-template-for-intervention-review-biqrkdv6","forks_count":{"private":0,"public":0},"access":{"can_view":1,"can_remove":0,"can_add":0,"can_edit":0,"can_publish":0,"can_get_doi":0,"can_share":1,"can_move":1,"can_move_outside":1,"can_transfer":1,"can_download":1,"is_locked":0},"guid":"A2B9FFE0C87C11EAA11EFF1D7739201C","state_version_id":43,"steps":[],"document":"<div class = \"text-blocks\"><div class = \"text-block\"><span>Title: : a systematic review and meta-analysi<\/span><a href=\"\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;:;\">s<\/span><\/a><a href=\"#_msocom_1\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca11]<\/span><\/a><span> protocol<\/span><\/div><div class = \"text-block\">\u30d7\u30ed\u30c8\u30b3\u30eb\u767b\u9332\u306e\u969b\u306e\u30e1\u30f3\u30bf\u30fc\u306eaffiliation \u62c5\u5f53\u306e\u307f\u3092\u8a18\u8f09<\/div><div class = \"text-block\">Yasushi Tsujimoto MD, MPH<\/div><div class = \"text-block\">1 Department of Nephrology and Dialysis, Kyoritsu Hospital, Chuo-cho 16-5, Kawanishi 666-0016 JAPAN<\/div><div class = \"text-block\">2 Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan.<\/div><div class = \"text-block\">3 Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">yssh0108@yahoo.co.jp <\/div><div class = \"text-block\">Masahiro Banno MD, PhD<\/div><div class = \"text-block\">1 Department of Psychiatry, Seichiryo Hospital, Tsurumai 4-16-27, Showa-ku, Nagoya 466-0064 JAPAN<\/div><div class = \"text-block\">2 Department of Psychiatry, Nagoya University Graduate School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya 466-8560 JAPAN<\/div><div class = \"text-block\">3 Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">solvency@med.nagoya-u.ac.jp <\/div><div class = \"text-block\">Yuki Kataoka MD, MPH, DrPH<\/div><div class = \"text-block\">1 Hospital Care Research Unit, Hyogo Prefectural Amagasaki General Medical Center, Higashinaniwa-cho 2-17-77, Amagasaki 660-8550 JAPAN<\/div><div class = \"text-block\">2 Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 606-8501 JAPAN<\/div><div class = \"text-block\">3 Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">4 Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Medical Center, Higashinaniwa-cho 2-17-77, Amagasaki 660-8550 JAPAN<\/div><div class = \"text-block\">youkiti@gmail.com<\/div><div class = \"text-block\">Shunsuke Taito PT PhD<\/div><div class = \"text-block\">1 Division of Rehabilitation, Department of Clinical Practice and Support, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, Hiroshima, 734-8551 Japan<\/div><div class = \"text-block\">2 Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">shutaitou@gmail.com<\/div><div class = \"text-block\">Ryuhei So MD, MPH<\/div><div class = \"text-block\">1 Department of Psychiatry, Okayama Psychiatric Medical Center, Shikatahonmachi 3-16, Kita -ku, Okayama, 700-0915 Japan<\/div><div class = \"text-block\">2 Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">nexttext@gmail.com <\/div><div class = \"text-block\">Jun Watanabe MD, PhD<\/div><div class = \"text-block\">1. Department of Surgery, Tottori Prefectural Central Hospital, 730 Ezu Tottori City, Tottori, 680-0901 Japan<\/div><div class = \"text-block\">2. Center for Community Medicine, Jichi Medical University, 3311-1 Yakushiji Shimotsuke City, Tochigi, 329-0498 Japan<\/div><div class = \"text-block\">3. Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">m06105jw@jichi.ac.jp<\/div><div class = \"text-block\">Akihiro Shiroshita MD<\/div><div class = \"text-block\">1. Department of respiratory medicine,Icinomiyanishi hospital, Ichinomiya,Kaimeihira 1,Ichinomiya-shi,494-0001, Japan<\/div><div class = \"text-block\">2. Systematic Review Workshop Peer Support Group (SRWS-PSG), Japan<\/div><div class = \"text-block\">akihirokun8@gmail.com<\/div><div class = \"text-block\">Corresponding author: \u3042\u306a\u305f\u306e\u540d\u524d<\/div><div class = \"text-block\">Address: <\/div><div class = \"text-block\">E-mail: <\/div><div class = \"text-block\">Author contributions:<\/div><div class = \"text-block\">??is the guarantor. ?? drafted the manuscript.<\/div><div class = \"text-block\">All authors contributed to the development of the selection criteria, the risk of bias assessment strategy and data extraction criteria. ??developed the search strategy. ?? provided statistical expertise. ?? provided expertise on ??. All authors read, provided feedback and approved the final manuscript.<\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><span>Support:<\/span><a href=\"#_msocom_2\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca12]<\/span><\/a><span><\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><\/div><\/div><div class = \"text-block\">1.Introduction<\/div><div class = \"text-block\">2.Research question<\/div><div class = \"text-block\">P: <\/div><div class = \"text-block\">I: <\/div><div class = \"text-block\">C:<\/div><div class = \"text-block\">O: <\/div><div class = \"text-block\">3.Method<\/div><div class = \"text-block\">3.1 Protocol<\/div><div class = \"text-block\"><span>We used a systematic review protocol template<\/span><a href=\"\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;:;\">.<\/span><\/a><a href=\"#_msocom_3\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca13]<\/span><\/a><a href=\"#_msocom_4\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[TY4]<\/span><\/a><span> We followed the Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 for preparing this protocol.<\/span><span style = \":;vertical-align:super;\">1<\/span><a href=\"#_msocom_5\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca15]<\/span><\/a><span> We will publish this protocol in protocols.io (<\/span><a href=\"https:\/\/www.protocols.io\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">https:\/\/www.protocols.io\/<\/span><\/a><span>).<\/span><\/div><div class = \"text-block\">3.2 Inclusion criteria of the articles for the review<\/div><div class = \"text-block\">3.2.1 Type of studies<\/div><div class = \"text-block\">We will include randomized controlled trials that assess ??????. We will not apply language or country restrictions. We will include all papers including published, unpublished articles, abstract of conference and letter.<\/div><div class = \"text-block\">We will exclude ??????. We will not exclude studies based on the observation period or publication year.<\/div><div class = \"text-block\">3.2.2 Study participants<\/div><div class = \"text-block\">??????<\/div><div class = \"text-block\">Inclusion criteria:<\/div><div class = \"text-block\">??????<\/div><div class = \"text-block\">Exclusion criteria:<\/div><div class = \"text-block\">??????<\/div><div class = \"text-block\">3.2.3 Intervention<\/div><div class = \"text-block\">3.2.4 Control<\/div><div class = \"text-block\">3.3 Type of outcomes<\/div><div class = \"text-block\">3.3.1 Primary outcomes<\/div><div class = \"text-block\">1.<\/div><div class = \"text-block\">Definition: <\/div><div class = \"text-block\">Period: <\/div><div class = \"text-block\">2. <\/div><div class = \"text-block\">Definition: <\/div><div class = \"text-block\">Period: <\/div><div class = \"text-block\">3. <\/div><div class = \"text-block\">Definition: <\/div><div class = \"text-block\">Period: <\/div><div class = \"text-block\">3.3.2 Secondary outcomes<\/div><div class = \"text-block\">1. <\/div><div class = \"text-block\">Definition: <\/div><div class = \"text-block\">Period: <\/div><div class = \"text-block\">2. <\/div><div class = \"text-block\">Definition: <\/div><div class = \"text-block\">Period: <\/div><div class = \"text-block\">3. All adverse events<\/div><div class = \"text-block\">Definition: definition of adverse events are set by original authors.<\/div><div class = \"text-block\">Incidence proportion of all adverse events<\/div><div class = \"text-block\">Period: during follow up period<\/div><div class = \"text-block\">3.4 Search method<\/div><div class = \"text-block\">3.4.1 Electronic search<\/div><div class = \"text-block\">We will search the following databases:<\/div><div class = \"text-block\">1. the Cochrane Central Register of Controlled Trials (CENTRAL);<\/div><div class = \"text-block\">2. MEDLINE via PubMed;<\/div><div class = \"text-block\">3. EMBASE via ProQuest Dialog;<\/div><div class = \"text-block\">See Appendix 1, 2, and 3 for the search strategies.<\/div><div class = \"text-block\">3.4.2 Other resources<\/div><div class = \"text-block\">We will also search the following databases for ongoing or unpublished trials:<\/div><div class = \"text-block\">1. the World Health Organization International Clinical Trials Platform Search Portal (ICTRP);<\/div><div class = \"text-block\">2. ClinicalTrials.gov;<\/div><div class = \"text-block\">See Appendix 4, 5 for the search strategies.<\/div><div class = \"text-block\">We will check the reference lists of studies, including international guidelines ?? as well as the reference lists of eligible studies and articles citing eligible studies. We will ask the authors of original studies for unpublished or additional data.<\/div><div class = \"text-block\">3.5 Data collection and analysis<\/div><div class = \"text-block\">3.5.1 Selection of the studies<\/div><div class = \"text-block\"><span>Two independent reviewers (??) will screen titles and abstracts, followed by the assessment of the eligibility based on the full texts<\/span><a href=\"\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;:;\">.<\/span><\/a><a href=\"#_msocom_6\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca16]<\/span><\/a><span> We will contact original authors if relevant data is missing. Disagreements between the two reviewers will be resolved by discussion, and if this fails, a third reviewer will act as an arbiter (??).<\/span><\/div><div class = \"text-block\">3.5.2 Data extraction and management<\/div><div class = \"text-block\">Two reviewers (??) will perform independent data extraction of the included studies using standardized data collection form. We will use a pre-checked form using 10 randomly selected studies. <\/div><div class = \"text-block\"><span>The form will include the information on <\/span><a href=\"\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">study design, study population, interventions and outcomes<\/span><\/a><a href=\"#_msocom_7\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca17]<\/span><\/a><span>. Any disagreements will be resolved by discussion, and if this fails, a third reviewer will act as an arbiter (??). <\/span><\/div><div class = \"text-block\">3.6 Assessment of risk of bias in included studies<\/div><div class = \"text-block\"><span>Two reviewers (??) will evaluate the risk of bias independently using the Risk of Bias 2.<\/span><span style = \"vertical-align:super;\">2<\/span><span> Disagreements between the two reviewers will be discussed, and if this fails, a third reviewer (??) will be acting as an arbiter, if necessary.<\/span><\/div><div class = \"text-block\">3.7 Measures of treatment effects<\/div><div class = \"text-block\">We will pool the relative risk ratios and the 95% confidence intervals (CIs) for the following binary variables: <\/div><div class = \"text-block\">We will pool the mean differences and the 95% CIs for the following continuous variables: <\/div><div class = \"text-block\">If several different scales have been used in the included studies, we will pool the effect estimates using standard mean differences (SMDs)<\/div><div class = \"text-block\">We will summarize adverse events based on the definition by the original article, but we will not perform meta-analysis..<\/div><div class = \"text-block\">3.8 Unit of analysis issues<\/div><div class = \"text-block\">Clustering at the level of the enrolled units in clusterrandomised studies <\/div><div class = \"text-block\"><span>In dealing with cluster-RCTs, for dichotomous data, we will applythe design effect and calculate effective sample size and number of events using the intracluster correlation coefficient (ICC) among each unit and the average cluster size, as described in Chapter 16.3.5 of the Cochrane Handbook.<\/span><span style = \"vertical-align:super;\">3<\/span><span> If the ICC has not been reported, we will use the ICC of a similar study as a substitute. For continuous data, only the sample size will be reduced; means and standard deviation will remain unchanged.<\/span><span style = \"vertical-align:super;\">3<\/span><\/div><div class = \"text-block\">Randomised cross-over studies<\/div><div class = \"text-block\">We will consider only data from the first period.<\/div><div class = \"text-block\">Multiple comparisons<\/div><div class = \"text-block\">All intervention groups that are relevant to this review will be included.<\/div><div class = \"text-block\">3.9 Handling of missing data<\/div><div class = \"text-block\">We will ask not-presented data to the original authors.<\/div><div class = \"text-block\">3.9.1 Missing outcomes<\/div><div class = \"text-block\">We will perform the intention-to-treat (ITT) analysis for all dichotomous data as much as possible.<\/div><div class = \"text-block\"><span>For continuous data, we will not impute missing data based on the recommendation by Cochrane handbook.<\/span><span style = \"vertical-align:super;\">3<\/span><span> We will perform meta-analysis about the available data in the original study.<\/span><\/div><div class = \"text-block\">3.9.2 Missing statistics<\/div><div class = \"text-block\"><span>When original studies only report standard error or p-value, we will calculate the standard deviation based on the method by Altman.<\/span><span style = \"vertical-align:super;\">4<\/span><span> If we don't know these values when we contact the authors, standard deviation will be calculated by confidence interval and t-value based on the method by Cochrane handbook<\/span><span style = \"vertical-align:super;\">3<\/span><span>, or validated method.<\/span><span style = \"vertical-align:super;\">4<\/span><span> Validity of these methods will be analyzed by sensitivity analysis.<\/span><\/div><div class = \"text-block\">3.10 Assessment of heterogeneity<\/div><div class = \"text-block\">We will evaluate the statistical heterogeneity by visual inspection of the forest plots and calculating the I2 statistic (I2 values of 0% to 40%: might not be important; 30%to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity). When there is substantial heterogeneity (I2> 50%), we will assess the reason of the heterogeneity. Cochrane Chi2test (Q-test) will be performed for I2 statistic, and P value less than 0.10 will be defined as statistically significant.<\/div><div class = \"text-block\">3.11 Assessment of reporting bias<\/div><div class = \"text-block\">We will search the clinical trial registry system (ClinicalTrials.gov and ICTRP) and will perform extensive literature search for unpublished trials. We will assess the potential publication bias by visual inspection of the funnel plot. Egger test will be performed as well. We will not conduct the test when we find less than 10 trials or trials which have similar sample size. We will assess the potential publication bias by visual inspection of the funnel plot<\/div><div class = \"text-block\">3.12 Meta-analysis<\/div><div class = \"text-block\">Meta-analysis will be performed using Review Manager software (RevMan 5.4). We will use a random-effects model.<\/div><div class = \"text-block\">3.13 Subgroup analysis<\/div><div class = \"text-block\">To elucidate the influence of effect modifiers on results, we will evaluate the subgroup analyses of the primary outcomes on the following factors when sufficient data are available.<\/div><div class = \"text-block\"><span>1. (For participants) ??<\/span><a href=\"#_msocom_8\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u88d5\u8cb48]<\/span><\/a><span><\/span><\/div><div class = \"text-block\">2. (For intervention) ??<\/div><div class = \"text-block\">3.14 Sensitivity analysis<\/div><div class = \"text-block\">We will undertake the following sensitivity analyses for the primary outcomes to assess whether the results of the review are robust to the decisions made during the review process. <\/div><div class = \"text-block\">1. Exclusion of studies using imputed statistics.<\/div><div class = \"text-block\"><span>2. Missing participants: verify the robustness of the results by seeking informative missingness odds ratios.<\/span><span style = \"vertical-align:super;\">5<\/span><\/div><div class = \"text-block\">3. Only the participants who complete the study with complete data<\/div><div class = \"text-block\">4. Summary of findings table<\/div><div class = \"text-block\"><span>Summary of findings table will be made for the following outcome based on the Cochrane handbook.<\/span><span style = \"vertical-align:super;\">3<\/span><\/div><div class = \"text-block\"><span>We will include grading to evaluate the quality of evidence based on the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach for each Summary of findings table.<\/span><span style = \"vertical-align:super;\">6<\/span><\/div><div class = \"text-block\">1. ??<\/div><div class = \"text-block\">5. Conflict of Interest<\/div><div class = \"text-block\">The authors declare no conflicts of interests.<\/div><div class = \"text-block\">References<\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><span>1. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. <\/span><span style = \"font-style:italic;\">BMJ<\/span><span>. 2015;349(jan02 1):g7647-g7647. doi:10.1136\/bmj.g7647<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><span>2. Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. <\/span><span style = \"font-style:italic;\">BMJ<\/span><span>. August 2019:l4898. doi:10.1136\/bmj.l4898<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\">3. Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019.<\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><span>4. Furukawa T a, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. <\/span><span style = \"font-style:italic;\">J Clin Epidemiol<\/span><span>. 2006;59(1):7-10. doi:10.1016\/j.jclinepi.2005.06.006<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><span>5. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. <\/span><span style = \"font-style:italic;\">Clin Trials J Soc Clin Trials<\/span><span>. 2008;5(3):225-239. doi:10.1177\/1740774508091600<\/span><\/div><\/div><div class = \"text-block\"><div class = \"justify\" style = \"text-align:left\"><span>6. Guyatt G, Oxman AD, Akl E a, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. <\/span><span style = \"font-style:italic;\">J Clin Epidemiol<\/span><span>. 2011;64(4):383-394. doi:10.1016\/j.jclinepi.2010.04.026<\/span><\/div><\/div><div class = \"text-block\">Appendix 1: CENTRAL search strategy<\/div><div class = \"text-block\">Appendix 2: MEDLINE (via PubMed) search strategy<\/div><div class = \"text-block\">Appendix 3: EMBASE (via ProQuest Dialog) search strategy<\/div><div class = \"text-block\">Appendix 4: ICTRP search strategy<\/div><div class = \"text-block\">Appendix 5: ClinicalTrials.gov search strategy<\/div><div class = \"text-block\">Condition or disease: <\/div><div class = \"text-block\">Intervention: <\/div><div class = \"text-block\"><a href=\"#_msoanchor_1\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca11]<\/span><\/a><span>\u4ecb\u5165\u306e\u30ec\u30d3\u30e5\u30fc\u3067\u3001RCT\u306e\u307f\u3092\u7d44\u307f\u5165\u308c\u308b\u5834\u5408\u306f\"efficacy\"\u3092\u30bf\u30a4\u30c8\u30eb\u3067\u4f7f\u3063\u3066\u304f\u3060\u3055\u3044\n\u7406\u7531\uff1a\n<\/span><a href=\"https:\/\/www.google.com\/url?q=https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC351867\/&sa=D&ust=1594860407020000&usg=AFQjCNEbd7fB7ArzPpXRT4Xn4ANCV2jvag\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC351867\/<\/span><\/a><span>\n\n\n\n<\/span><a href=\"#_msoanchor_2\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca12]<\/span><\/a><span>\u8cc7\u91d1\u6e90\u304c\u3042\u308c\u3070\u3001\u305d\u306e\u5f79\u5272\u3092\n\u306a\u304f\u3066\u3082\u3001self funding\u3068\u66f8\u304d\u307e\u3057\u3087\u3046\n\n\n<\/span><a href=\"#_msoanchor_3\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca13]<\/span><\/a><span>\u3053\u306e\u30c6\u30f3\u30d7\u30ec\u3092protocols.io\u306b\u51fa\u7248\u3057\u3066\u3057\u307e\u3063\u3066\u3001\u305d\u306e\u5f15\u7528\u3068\u3057\u3066\u66f8\u3044\u3066\u3082\u3089\u3046\u5f62\u5f0f\u306f\u3069\u3046\u3067\u3057\u3087\u3046\u304b\uff1f\n\n\n\u3044\u3044\u3068\u601d\u3044\u307e\u3059\uff01<\/span><a href=\"#_msoanchor_4\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[TY4]<\/span><\/a><span>\n\n\n<\/span><a href=\"#_msoanchor_5\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca15]<\/span><\/a><span>\u3053\u3053\u304b\u3089\u306ecitation\u306fMendeley\u3067\u5165\u308c\u3066\u3042\u308a\u307e\u3059\n\n\n<\/span><a href=\"#_msoanchor_6\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca16]<\/span><\/a><span>3\u4eba\u4ee5\u4e0a\u306a\u3089\u3001two of three independent\uff5e\n\n\n<\/span><a href=\"#_msoanchor_7\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca17]<\/span><\/a><span>\u3053\u3053\u306f\u53ef\u80fd\u306a\u9650\u308a\u8a73\u7d30\u3092\u66f8\u3044\u3066\u304f\u3060\u3055\u3044<\/span><a href=\"#_msoanchor_7\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u7247\u5ca17]<\/span><\/a><span>\n\n\n<\/span><a href=\"#_msoanchor_8\" style = \"text-decoration:underline;color:blue;cursor:pointer;\"><span style = \":;\">[\u88d5\u8cb48]<\/span><\/a><span>A vs. B \u306e\u3088\u3046\u306b\u30ab\u30c3\u30c8\u30aa\u30d5\u3092\u306f\u3063\u304d\u308a\u3055\u305b\u3066\u8a18\u8ff0\u3059\u308b\u3053\u3068\n\n\n<\/span><\/div><\/div>","materials":[],"description":null,"changed_on":1595025161}